Alivus Life Sciences Ltd
Thu 13/03/2025,15:59:10 | NSE : ALIVUS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1017.45
Previous Close
₹ 1017.45
Volume
58851
Mkt Cap ( Rs. Cr)
₹12547.79
High
₹ 1038.90
Low
₹ 986.00
52 Week High
₹ 1335.10
52 Week Low
₹ 676.50
Book Value Per Share
₹ 207.16
Dividend Yield
0.00
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Alivus Life Sciences Ltd
Your Vote -
Buy
90.78%
Hold
7.28%
Sell
1.94%
90.78%
206 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Alivus Life Sciences - Alteration Of Capital and Fund Raising-XBRL
-
Alivus Life Sciences - ESOP/ESOS/ESPS
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alivus Life Sciences - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alivus Life Sciences - Demise
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Alivus Life Sciences - Action(s) initiated or orders passed
-
Alivus Life Sciences - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alivus Life Sciences - General Updates
-
Alivus Life Sciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulatio
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Integrated Filing- Financial
-
Alivus Life Sciences - Investor Presentation
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Alivus Life Sciences - Press Release
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Alivus Life Sciences - Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2024
-
Alivus Life Sciences - Financial Result Updates
-
Alivus Life Sciences - Integrated Filing (Financial)
-
Alivus Life Sciences Q3 net profit up 15.32% at Rs 136.96 cr
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Alivus Life Sciences - Trading Window-XBRL
-
Alivus Life Sciences - Board Meeting Intimation
-
Alivus Life Sciences - Trading Window
-
Alivus Life Sciences - Board Meeting Intimation for Inter Alia, To Consider And Approve The Unaudited Financial Results Of Th
-
Alivus Life Sciences - Name and Symbol Change
-
Glenmark Life Scienc - Name Change
-
Glenmark Life Scienc - Announcement under Regulation 30 (LODR)-Change of Company Name
-
Glenmark Life Science
-
Glenmark Life signs master supply agreement with a Japanese innovator pharma co
-
Glenmark Lifesciences
-
Glenmark Life Sciences report strong Q1 earnings
Key fundamentals
Evaluate the intrinsic value of Alivus Life Sciences Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 2332.322 | 2138.207 | 2054.312 | 752.747 | 401.713 |
| Liabilities | 2332.322 | 2138.207 | 2054.312 | 752.747 | 401.713 |
| Equity | 24.505 | 24.505 | 24.505 | 1.96 | 1.96 |
| Gross Profit | 674.246 | 642.293 | 616.06 | 591.074 | 471.96 |
| Net Profit | 470.888 | 466.961 | 418.724 | 351.581 | 313.098 |
| Cash From Operating Activities | 413.515 | 313.404 | 597.585 | 388.113 | 195.007 |
| NPM(%) | 20.62 | 21.6 | 19.72 | 18.64 | 20.36 |
| Revenue | 2283.214 | 2161.22 | 2123.214 | 1885.165 | 1537.313 |
| Expenses | 1608.968 | 1518.927 | 1507.154 | 1294.091 | 1065.353 |
| ROE(%) | 18.54 | 18.39 | 16.49 | 13.85 | 12.33 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 17 Oct 2023 | 22.5 | 1125 | 0 | 617.7 |
| 24 Mar 2023 | 21 | 1050 | 0 | 375.3 |
| 15 Sep 2022 | 10.5 | 525 | 0 | 489 |
| 22 Nov 2021 | 10.5 | 525 | 0 | 632.7 |
Peers
Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 808.20 | -1.14 | 11.41 | 584.36 | 1321.50 | 1.42 |
| Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 2129.33 | 14.01 | 0.88 |
| Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 1097.54 | 2.31 | 0.00 |
| Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 2007.78 | -239.30 | 0.00 |
Company Info
The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.
The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.
Read More
Parent Organisation
Alivus Life Sciences Ltd.
Founded
23/06/2011
Managing Director
Dr.Yasir Rawjee
NSE Symbol
ALIVUSEQ
FAQ
The current price of Alivus Life Sciences Ltd is ₹ 1024.00.
The 52-week high for Alivus Life Sciences Ltd is ₹ 1038.90 and the 52-week low is ₹ 986.00.
The market capitalization of Alivus Life Sciences Ltd is currently ₹ 12547.79. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Alivus Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Alivus Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alivus Life Sciences Ltd shares.
The CEO of Alivus Life Sciences Ltd is Dr.Yasir Rawjee, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
